182127-92-0

Basic information

• Product Name: 2-MERCAPTO-6-METHYL-4-(TRIFLUOROMETHYL)NICOTINONITRILE
• Synonyms: 2-MERCAPTO-6-METHYL-4-(TRIFLUOROMETHYL)NICOTINONITRILE;AKOS BBS-00000377;3-Pyridinecarbonitrile,1,2-dihydro-6-Methyl-2-thioxo-4-(trifluoroMethyl)-;1,2-dihydro-6-methyl-2-thioxo-4-((trifluoromethyl))-pyridin-3-carbonitrile
• CAS NO: 182127-92-0
• Molecular Formula: C₈H₅F₃N₂S
• Molecular Weight: 218.2
• Mol File: 182127-92-0.mol
• Article Data: 6

Chemical Properties

• Melting Point: 200 °C
• Boiling Point: 204.4°Cat760mmHg
• Flash Point: 77.4°C
• Appearance: /
• Density: 1.44g/cm³
• Vapor Pressure: 0.263mmHg at 25°C
• Refractive Index: 1.536
• CAS DataBase Reference: 2-MERCAPTO-6-METHYL-4-(TRIFLUOROMETHYL)NICOTINONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-MERCAPTO-6-METHYL-4-(TRIFLUOROMETHYL)NICOTINONITRILE(182127-92-0)
• EPA Substance Registry System: 2-MERCAPTO-6-METHYL-4-(TRIFLUOROMETHYL)NICOTINONITRILE(182127-92-0)

Safety Data

• Hazard Codes: T
• Statements: 36/37/38-25
• Safety Statements: 26-36/37/39-45
• Hazardous Substances Data: 182127-92-0(Hazardous Substances Data)

Usage

General Description

"2-Mercapto-6-methyl-4-(trifluoromethyl)nicotinonitrile" is a chemical compound with the molecular formula C8H6F3N3S. It is a derivative of nicotinonitrile, which is commonly used in organic synthesis and pharmaceutical research. The presence of a mercapto group and a trifluoromethyl group in the molecule makes it useful in various biochemical and pharmaceutical applications. It can act as a versatile building block for the synthesis of potential drug candidates and other biologically active compounds. The compound's unique structure and reactivity make it a valuable tool for medicinal chemistry and drug discovery efforts.

InChI:InChI=1/C8H5F3N2S/c1-4-2-6(8(9,10)11)5(3-12)7(14)13-4/h2H,1H3,(H,13,14)

Upstream product

• 7357-70-2 Cyanothioacetamide 
• 144864-94-8 5,5,5-trifluoro-4-hydroxy-pent-3-en-2-one 
• 234112-44-8 4-methoxy-1,1,1-trifluoropent-3-en-2-one 
• 135351-20-1 1,1,1-trifluoro-4-methoxypent-3-en-2-one 
• 367-57-7 1,1,1-Trifluoro-2,4-pentanedione 

Downstream Products

• 206280-69-5 2-(3-Cyano-6-methyl-4-trifluoromethyl-pyridin-2-ylsulfanyl)-N-p-tolyl-acetamide 
• 313379-68-9 methyl 3-amino-6-methyl-4-(trifluoromethyl)thieno[2,3-b]pyridine-2-carboxylate 
• 610259-30-8 3-amino-6-methyl-4-(trifluoromethyl)thieno[2,3-b]pyridine-2-carboxylic acid 
• 299198-61-1 ethyl 3-amino-6-methyl-4-(trifluoromethyl)thieno[2,3-b]pyridine-2-carboxylate 
• 206280-68-4 2-(3-Cyano-6-methyl-4-trifluoromethyl-pyridin-2-ylsulfanyl)-N-phenyl-acetamide 
• 206280-70-8 N-(3-Butoxy-phenyl)-2-(3-cyano-6-methyl-4-trifluoromethyl-pyridin-2-ylsulfanyl)-acetamide 
• 182127-95-3 6-Methyl-2-(2-oxo-2-phenyl-ethylsulfanyl)-4-trifluoromethyl-nicotinonitrile 

Relevant articles and documents

CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS

The present disclosure relates to modulators, such as inhibitors, of at least one pathway chosen from USP28 and USP25, pharmaceutical compositions comprising the inhibitors, and methods of using the inhibitors. The modulators, such as inhibitors, of at least one pathway chosen from USP28 and USP25 can be useful in the treatment of cancers, among other ailments.

Discovery and structure-activity relationships study of thieno[2,3-b]pyridine analogues as hepatic gluconeogenesis inhibitors

Type 2 diabetes mellitus (T2DM) is a chronic, complex and multifactorial metabolic disorder, and targeting gluconeogenesis inhibition is a promising strategy for anti-diabetic drug discovery. This study discovered a new class of thieno[2,3-b]pyridine derivatives as hepatic gluconeogenesis inhibitors. First, a hit compound (DMT: IC50 = 33.8 μM) characterized by a thienopyridine core was identified in a cell-based screening of our privileged small molecule library. Structure activity relationships (SARs) study showed that replaced the CF3 in the thienopyridine core could improve the potency and led to the discovery of 8e (IC50 = 16.8 μM) and 9d (IC50 = 12.3 μM) with potent inhibition of hepatic glucose production and good drug-like properties. Furthermore, the mechanism of 8e for the inhibition of hepatic glucose production was also identified, which could be effective through the reductive expression of the mRNA transcription level of gluconeogenic genes, including glucose-6-phosphatase (G6Pase) and hepatic phosphoenolpyruvate carboxykinase (PEPCK). Additionally, 8e could also reduce the fasting blood glucose and improve the oral glucose tolerance and pyruvate tolerance in db/db mice. The optimization of this class of derivatives had provided us a start point to develop new anti-hepatic gluconeogenesis agents.

Regioselective synthesis and properties of 3-cyano-6-methyl-4-trifluoromethylpyridine-2(1H)-thione. Molecular and crystal structure of 3-cyano-2-ethylthio-6-methyl-4-trifluoromethylpyridine

The reaction of trifluoroacetylacetone with cyanothioacetamide proceeded regioselectively to form 3-cyano-6-methyl-4-trifluoromethylpyridine-2(1H)-thione from which the corresponding 2-alkylthiopyridines and 3-aminothieno[2,3-b]pyridines were obtained. The crystal and molecular structure of 3-cyano-2-ethylthio-6-methyl-4-trifluoromethylpyridine was established by X-ray diffraction analysis.